ABOUT THE HOPKINS CAPITAL GROUP
Johns Hopkins was a successful Baltimore entrepreneur and investor whose business fortune helped start a world class university, including a hospital uniquely committed to the care of the disadvantaged. This great philanthropist is our inspiration. Accordingly, the principals of The Hopkins Capital Group are committed to the entrepreneurial spirit of Johns Hopkins, recognizing that future cures have their origins in the support of promising, albeit sometimes controversial, innovations in healthcare technologies. In the spirit of Johns Hopkins, we feel that philanthropy is important. It informs what technologies we support. Also, we feel that potential cures should not be denied to any patients simply because they cannot afford to pay.
The Hopkins Capital Group is an affiliation of private investment companies organized as limited liability companies to hold one or more healthcare technology companies. Like a private foundation, Hopkins Capital Group has a mission, which defines its scope of interest and which enables it to take on more risk in these investments because the total return is a combination of economic and social gain. We are exclusively devoted to the development of significant breakthrough technologies in healthcare. Our passion for development of these technologies is driven by our desire to use our capital and our talents to make a difference in this world. Hopkins Capital Group does not solicit nor accept outside investors. Our longtime investors are philanthropically minded, high net-worth individuals, family offices, trusts, and family partnerships. We invest with a long-term perspective much like an endowment. Accordingly, we prefer to co-invest with other sources of philanthropic capital, such as private foundations.
We are focused principally on identifying, organizing, financing, and developing disruptive technologies in healthcare. By disruptive, we mean technologies that are typically based on a paradigm shift in the pathogenesis, diagnosis, or treatment of human disease. As such, these technologies engender substantial skepticism, and they can be particularly challenging to bring to market. On the other hand, if valid, they typically dominate the market. We are focused principally on potential cures.
Our current portfolio includes three publicly-traded companies (see links) as well as a number of privately-held companies.
*Disclaimer: The Hopkins Capital Group is not affiliated with Johns Hopkins University